# US 2020/0399613 A1 · Cell Mass Fusion Method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0399613 A1
- Document ID: US20200399613A1
- Status: Published application
- Kind: A1
- Application number: 16/969,523
- Filed: 2019-03-27
- Published: 2020-12-24
- Earliest claimed: 2018-03-28
- Assignees: Public University Corporation Yokohama City University
- Applicants: Public University Corporation Yokohama City University
- Inventors: Hideki Taniguchi; Tomomi Tadokoro
- Web page: https://patentgrep.com/patent/US20200399613A1

## CPC

- C12N 5/16: Animal cells
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/407: Liver; Hepatocytes
- C12N 5/0662: {Stem cells}
- C12N 5/0668: {Mesenchymal stem cells from other natural sources}
- C12N 5/0671: {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
- C12N 5/069: {Vascular Endothelial cells}
- C12N 5/0697: {Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N5/0691)}
- C12N 2501/065: Modulators of histone acetylation
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2513/00: 3D culture
- C12N 2533/52: Fibronectin; Laminin
- C12N 2533/54: Collagen; Gelatin
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a method of fusing cell masses. A method of fusing cell masses, comprising seeding cell masses on a plane capable of cell adhesion and culturing the cell masses as a culture medium is fed from both the obverse and reverse sides of the cell mass-seeded plane.

## Claims

### Claim 1

A method of fusing cell masses, comprising seeding cell masses on a plane capable of cell adhesion and culturing the cell masses as a culture medium is fed from both the obverse and reverse sides of the cell mass-seeded plane.

### Claim 2 (depends on 1)

The method of claim 1, wherein cell masses are seeded on the plane capable of cell adhesion in such a manner that the ratio of the area occupied by the cell masses to the seeded plane is 40 to 100%.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cell mass comprises vascular cells and/or mesenchymal cells.

### Claim 4 (depends on 3)

The method claim 3, wherein the ratio of mesenchymal cells to vascular cells is 1:0.01-100.

### Claim 5 (depends on 4)

The method of claim 4, wherein the ratio of mesenchymal cells to vascular cells is 1:0.1-10.

### Claim 6 (depends on 1)

The method of claim 1, wherein the resultant fused cell mass is forming a vascular network structure.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cell mass is an organ bud.

### Claim 8 (depends on 7)

The method of claim 7, wherein the organ bud has been formed from tissue or organ cells, mesenchymal cells and vascular cells.

### Claim 9 (depends on 8)

The method of claim 8, wherein the ratio of tissue or organ cells, mesenchymal cells and vascular cells is 10:0.1-10:0.1-10.

### Claim 10 (depends on 9)

The method of claim 9, wherein the ratio of mesenchymal cells to vascular cells is 1:0.1-10.

### Claim 11 (depends on 7)

The method of claim 7, wherein the organ bud has been formed in a culture vessel having a non-cell-adhesive plane.

### Claim 12 (depends on 7)

The method of claim 7, wherein the organ bud is a liver bud and the fused liver bud is forming a vascular network structure.

### Claim 13 (depends on 12)

The method of claim 12, wherein the vascular network structure comprises microvessels and/or arterioles/venules.

### Claim 14 (depends on 6)

The method of claim 6, wherein the organ bud is a liver bud and the fused liver bud is forming a bile duct structure.

### Claim 15

A method of preparing a fused cell mass, comprising seeding cell masses on a plane capable of cell adhesion and culturing the cell masses as a culture medium is fed from both the obverse and reverse sides of the cell mass-seeded plane to thereby fuse the cell masses.

### Claim 16

A method of constructing a vascular network structure, comprising seeding cell masses on a plane capable of cell adhesion and culturing the cell masses as a culture medium is fed from both the obverse and reverse sides of the cell mass-seeded plane to thereby form a vascular network structure.

### Claim 17

An artificial organ that is prepared by fusing liver buds in vitro as they have been formed from hepatocytes, mesenchymal cells and vascular cells and which has a vascular network structure and/or a bile duct structure.

### Claim 18 (depends on 17)

The artificial organ of claim 17, wherein at least one of the hepatocyte, the mesenchymal cell and the vascular cell has been generated by directed differentiation from induced pluripotent stem cells.
